RT Conference Proceedings
T1 Palbociclib, trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype (SOLTI-1303 PATRICIA II): A randomized phase II trial
A1 Ciruelos, E. M.
A1 Villagrasa, P.
A1 Oliveira, M.
A1 Pernas Simon, S.
A1 Cortes, J.
A1 Vazquez, S.
A1 Martinez, N.
A1 Perello, A.
A1 Bermejo De Las Heras, B.
A1 Martinez, E.
A1 Garau Llinas, I.
A1 Mele Olive, M.
A1 Montano, A.
A1 Vega, E.
A1 Cantos, B.
A1 Echarri, M. J.
A1 Pascual, T.
A1 Celiz, P.
A1 Gonzalez-Farre, X.
A1 Prat, A.
PB Elsevier
SN 0923-7534
YR 2020
FD 2020-05-01
LK https://hdl.handle.net/10668/27212
UL https://hdl.handle.net/10668/27212
LA en
DS RISalud
RD Apr 15, 2025